Search Within

Shanu Modi

  1. "Springer"
Formats
  1. Journal Article (11)
  2. Meeting Abstract (7)
Groups
  1. Breast Medicine Service (18)
  2. Department of Medicine (18)
  3. Solid Tumor Oncology Division (18)
  4. Survivorship Research (11)
  5. GSK Faculty (6)
  6. Department of Pathology and Laboratory Medicine (4)

More Groups

People
  1. Clifford Hudis (7)
  2. David Solit (3)
  3. Diana Lake (3)
  4. Mario Lacouture (3)
  5. Andrew Seidman (2)
  6. Jacqueline Bromberg (2)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2022 (1)
  4. 2020 (1)
  5. 2017 (1)
  6. 2015 (1)

More Years

Publications
  1. Breast Cancer Research and Treatment (14)
  2. Annals of Surgical Oncology (1)
  3. Current Breast Cancer Reports (1)
  4. Current Oncology Reports (1)
  5. Virchows Archiv (1)
Publishers
  1. Springer (18)

Results (18)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment patterns and outcomes in HER2-low metastatic breast cancer patients previously treated with chemotherapy: A US real-world cohort study
    Journal Article

    Modi, S.; Zhang, S.; Byng, D.; Hunter, S.; Strübing, A.; Xiong, Y.; Dunton, K.; Mbanya, Z.; Jacot, W.
    Breast Cancer Research and Treatment (2025)

    Fulltext@MSK | Save
  • Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer
    Journal Article

    Garrido, C.; Manoogian, M.; Ghambire, D.; Lucas, S.; Karnoub, M.; Olson, M. T.; Hicks, D. G.; Tozbikian, G.; Prat, A.; Ueno, N. T.; more...
    Virchows Archiv (2024)

    Fulltext@MSK | Save
  • Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients
    Journal Article

    Gu, S.; Dusza, S.; Quigley, E.; Haliasos, H.; Markova, A.; Marchetti, M.; Moy, A. P.; Dang, C.; Modi, S.; Lake, D.; more...
    Breast Cancer Research and Treatment (2024)

    Fulltext@MSK | Save
  • Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: A feasibility study
    Journal Article

    Walsh, E. M.; Gucalp, A.; Patil, S.; Edelweiss, M.; Ross, D. S.; Razavi, P.; Modi, S.; Iyengar, N. M.; Sanford, R.; Troso-Sandoval, T.; more...
    Breast Cancer Research and Treatment (2022)

    Fulltext@MSK | Save
  • Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer
    Journal Article

    Wang, D. G.; Barrios, D. M.; Blinder, V. S.; Bromberg, J. F.; Drullinsky, P. R.; Funt, S. A.; Jhaveri, K. L.; Lake, D. E.; Lyons, T.; Modi, S.; more...
    Breast Cancer Research and Treatment (2020)

    Fulltext@MSK | Save
  • Targeting HER2/3 in breast cancer
    Journal Article

    Hepner, A.; Modi, S.; Jhaveri, K.
    Current Breast Cancer Reports (2017)

    Fulltext@MSK | Save
  • The effect of molecular subtype and residual disease on locoregional recurrence in breast cancer patients treated with neoadjuvant chemotherapy and postmastectomy radiation
    Journal Article

    Yang, T. J.; Morrow, M.; Modi, S.; Zhang, Z.; Krause, K.; Siu, C.; McCormick, B.; Powell, S. N.; Ho, A. Y.
    Annals of Surgical Oncology (2015)

    Fulltext@MSK | Save
  • Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: A case series
    Journal Article

    Sibaud, V.; Niec, R. E.; Schindler, K.; Busam, K. J.; Roché, H.; Modi, S.; Delord, J. P.; Lacouture, M. E.
    Breast Cancer Research and Treatment (2014)

    Fulltext@MSK | Save
  • A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer
    Journal Article

    Modi, S.; Saura, C.; Henderson, C.; Lin, N. U.; Mahtani, R.; Goddard, J.; Rodenas, E.; Hudis, C.; O'Shaughnessy, J.; Baselga, J.
    Breast Cancer Research and Treatment (2013)

    Fulltext@MSK | Save
  • Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with Her2-positive trastuzumab-refractory metastatic breast cancer (MBC): Phase 2 trial
    Meeting Abstract

    Modi, S.; Stopeck, A.; Kinden, H.; Sugarman, S.; Ma, W.; Solit, D.; Kersey, K.; Johnson, R.; Hannah, A. L.; Hudis, C.
    Breast Cancer Research and Treatment (2007)

    Fulltext@MSK | Save